Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

281 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients.
Piñana JL, Vázquez L, Martino R, de la Cámara R, Sureda A, Rodríguez-Veiga R, Garrido A, Sierra J, Ribera JM, Torrent A, Mateos MV, de la Rubia J, Tormo M, Díez-Campelo M, García-Gutiérrez V, Álvarez-Larrán A, Sancho JM, MartínGarcía-Sancho A, Yañez L, Pérez Simón JA, Barba P, Abrisqueta P, Álvarez-Twose I, Bonanad S, Lecumberri R, Ruiz-Camps I, Navarro D, Hernández-Rivas JÁ, Cedillo Á, García-Sanz R, Bosch F. Piñana JL, et al. Among authors: de la rubia j, de la camara r. Leuk Lymphoma. 2022 Mar;63(3):538-550. doi: 10.1080/10428194.2021.1992619. Epub 2021 Oct 20. Leuk Lymphoma. 2022. PMID: 34668835 Free PMC article.
Prolonged molecular remission after PML/RAR alpha-positive autologous peripheral blood stem cell transplantation in acute promyelocytic leukemia: is relevant pretransplant minimal residual disease in the graft?
Sanz MA, de la Rubia J, Bonanad S, Barragán E, Sempere A, Martín G, Martínez JA, Jiménez C, Cervera J, Bolufer P, Sanz GF. Sanz MA, et al. Among authors: de la rubia j. Leukemia. 1998 Jun;12(6):992-5. doi: 10.1038/sj.leu.2401024. Leukemia. 1998. PMID: 9639431
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis.
Gutiérrez NC, Castellanos MV, Martín ML, Mateos MV, Hernández JM, Fernández M, Carrera D, Rosiñol L, Ribera JM, Ojanguren JM, Palomera L, Gardella S, Escoda L, Hernández-Boluda JC, Bello JL, de la Rubia J, Lahuerta JJ, San Miguel JF; GEM/PETHEMA Spanish Group. Gutiérrez NC, et al. Among authors: de la rubia j. Leukemia. 2007 Jan;21(1):143-50. doi: 10.1038/sj.leu.2404413. Epub 2006 Oct 5. Leukemia. 2007. PMID: 17024116 Clinical Trial.
Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.
Rosiñol L, Oriol A, Mateos MV, Sureda A, García-Sánchez P, Gutiérrez N, Alegre A, Lahuerta JJ, de la Rubia J, Herrero C, Liu X, Van de Velde H, San Miguel J, Bladé J. Rosiñol L, et al. Among authors: de la rubia j. J Clin Oncol. 2007 Oct 1;25(28):4452-8. doi: 10.1200/JCO.2007.12.3323. Epub 2007 Sep 4. J Clin Oncol. 2007. PMID: 17785704 Clinical Trial.
Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy.
Mateo G, Montalbán MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutiérrez N, Rosiñol L, Montejano L, Bladé J, Martínez R, de la Rubia J, Diaz-Mediavilla J, Sureda A, Ribera JM, Ojanguren JM, de Arriba F, Palomera L, Terol MJ, Orfao A, San Miguel JF; PETHEMA Study Group; GEM Study Group. Mateo G, et al. Among authors: de la rubia j, de arriba f. J Clin Oncol. 2008 Jun 1;26(16):2737-44. doi: 10.1200/JCO.2007.15.4120. Epub 2008 Apr 28. J Clin Oncol. 2008. PMID: 18443352 Clinical Trial.
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma.
Rosiñol L, Pérez-Simón JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ, González JD, Díaz-Mediavilla J, Hernández B, García-Frade J, Carrera D, León A, Hernández M, Abellán PF, Bergua JM, San Miguel J, Bladé J; Programa para el Estudio y la Terapéutica de las Hemopatías Malignas y Grupo Español de Mieloma (PETHEMA/GEM). Rosiñol L, et al. Among authors: de la rubia j, de arriba f. Blood. 2008 Nov 1;112(9):3591-3. doi: 10.1182/blood-2008-02-141598. Epub 2008 Jul 8. Blood. 2008. PMID: 18612103 Free article. Clinical Trial.
Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.
Lahuerta JJ, Mateos MV, Martínez-López J, Rosiñol L, Sureda A, de la Rubia J, García-Laraña J, Martínez-Martínez R, Hernández-García MT, Carrera D, Besalduch J, de Arriba F, Ribera JM, Escoda L, Hernández-Ruiz B, García-Frade J, Rivas-González C, Alegre A, Bladé J, San Miguel JF. Lahuerta JJ, et al. Among authors: de la rubia j, de arriba f. J Clin Oncol. 2008 Dec 10;26(35):5775-82. doi: 10.1200/JCO.2008.17.9721. Epub 2008 Nov 10. J Clin Oncol. 2008. PMID: 19001321
Imipenem/cilastatin with or without glycopeptide as initial antibiotic therapy for recipients of autologous stem cell transplantation: results of a Spanish multicenter study.
de la Rubia J, Montesinos P, Martino R, Jarque I, Rovira M, Vázquez L, López J, Batlle M, de la Cámara R, Juliá A, Lahuerta JJ, Debén G, Díaz J, García R, Sanz MA. de la Rubia J, et al. Among authors: de la camara r. Biol Blood Marrow Transplant. 2009 Apr;15(4):512-6. doi: 10.1016/j.bbmt.2008.12.505. Epub 2009 Feb 12. Biol Blood Marrow Transplant. 2009. PMID: 19285640 Free article.
281 results